Author

Richard G. Vile

Mayo ClinicORCID 0000-0003-2192-9372Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Benjamin Luke KendalliD· 2 shared Alan A. MelcheriD· 1 shared Aleksandra CiosiD· 1 shared Alex T Baker· 1 shared Alex Taylor· 1 shared Amarin WongariyapakiD· 1 shared Anton PatrikeeviD· 1 shared Antonio RullaniD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Benjamin Luke KendallORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Intratumoural oncolytic HSV-1 reshapes the local and systemic immune landscape through CD8+ T cell reprogramming

Elizabeth S. Appleton, Anton Patrikeev, Victoria Roulstone, Mikel Portillo, Jehanne Hassan, Shane Foo, Lisa Hubbard, Joan Kyula, Isaac Dean, Ernesto López, Charleen Chan Wah Hak, Malin Pedersen, Antonio Rullan, Chanidapa Adele Tye, Mark Allen, , Alan A. Melcher

This paper shows that intratumoural oncolytic HSV-1 reprograms systemic immunity by inducing specific CD8 T cell populations that correlate with clinical response to immunotherapy.

bioRxiv · May 29, 2026 · PreprintCancer Biology

Repeat Systemic Delivery of Cross-Neutralization Resistant Synthetic Vesiculoviruses Immunomodulates the Tumor Microenvironment

Natalie M. Elliott, Benjamin Luke Kendall, Souyma Dutta, Daipayan Sarkar, John Vant, Jill Thompson, Elizabeth A. Raupach, Christopher Shin, Khandoker Usran Ferdous, Aleksandra Cios, Kenneth H. Buetow, Chelsae R Watters, SangKon Oh, Autumn J. Schulze, Alex T Baker, , Mitesh J. Borad

A glycoprotein-engineered vesiculovirus platform circumvents neutralizing antibodies, enabling repeat intravenous dosing and sustained anti-tumor immunity in preclinical models.

bioRxiv · Aug 1, 2025 · PreprintMolecular Biology